The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
TP53 and KRAS Mutation Load and Types in Lung Cancers in Relation to Tobacco Smoke: Distinct Patterns in Never, Former, and Current Smokers
Open accessPublished version of a preprint
Abstract
TP53 mutations are common in lung cancers of smokers, with high prevalence of G:C-to-T:A transversions generally interpreted as mutagen fingerprints of tobacco smoke. In this study, TP53 (exons 5-9) and KRAS (codon 12) were analyzed in primary lung tumors of never (n = 40), former (n = 27), and current smokers (n = 64; mainly heavy smokers). Expression of p53, cyclooxygenase-2 (Cox-2), and nitrotyrosine (N-Tyr), a marker of protein damage by nitric oxide, were analyzed by immunohistochemistry. TP53 mutations were detected in 47.5% never, 55.6% former, and 77.4% current smokers. The relative risk for mutation increased with tobacco consumption (Plinear trend < 0.0001). G:C-to-T:A transversions (P = 0.06, current versus never smokers) and A:T-to-G:C transitions (P = 0.03, former versus never smokers) were consistently associated with smoking. In contrast, G:C-to-A:T transitions were associated with never smoking (P = 0.02). About half of mutations in current smokers fell within a particular domain of p53 protein, suggesting a common structural effect. KRAS mutations, detected in 20 of 131 (15.3%) cases, were rare in squamous cell carcinoma compared with adenocarcinoma [relative risk (RR), 0.2; 95% confidence interval (95% CI), 0.07-1] and were more frequent in former smokers than in other categories. No significant differences in Cox-2 expression were found between ever and never smokers. However, high levels of N-Tyr were more common in never than ever smokers (RR, 10; 95% CI, 1.6-50). These results support the notion that lung tumorigenesis proceeds through different molecular mechanisms according to smoking status. In never smokers, accumulation of N-Tyr suggests an etiology involving severe inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike other clinically actionable genomic alterations found in NSCLCs (such as EGFR and ALK aberrations), KRAS mutations, particularly KRASG12C and KRASG12V, are strongly associated with smoking29–31.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans
Carter, R. L. (1980) · Journal of Clinical Pathology · doi:10.1136/jcp.33.1.98-b · Cited by 3,455
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers
Pfeifer, G. P., Denissenko, M. F., Olivier, M., Tretyakova, N. Y., Hecht, S. S., & Hainaut, P. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205803 · Cited by 1,107
Self-citationBiochemistry, Biology, and Carcinogenicity of Tobacco-Specific N -Nitrosamines
Hecht, S. S. (1998) · Chemical Research in Toxicology · doi:10.1021/tx980005y · Cited by 1,074
Molecular Damage in the Bronchial Epithelium of Current and Former Smokers
Wistuba, I. I., Virmani, A. K., Gazdar, A. F., Lam, S. C., LeRiche, J., Behrens, C., Fong, K. M., Samet, J. M., Srivastava, S., & Minna, J. D. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.18.1366 · Cited by 487
Hainaut, P. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.367 · Cited by 375
Self-citationClinical significance of ras oncogene activation in human lung cancer
Therapy, E. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90536-7 · Cited by 361
Research works printed but not linked: 1
- Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002; 21: 7435–51. · DOI
Cited by
Sorted by citations
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Lung cancer in never smokers — a different disease
Sun, S., Schiller, J. H., & Gazdar, A. F. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2190 · Cited by 1,601
Mutational signatures associated with tobacco smoking in human cancer
Alexandrov, L. B., Ju, Y. S., Haase, K., Van Loo, P., Martincorena, I., Nik-Zainal, S., Totoki, Y., Fujimoto, A., Nakagawa, H., Shibata, T., et al. (2016) · Science · doi:10.1126/science.aag0299 · Cited by 1,100
Lung cancer in never smokers – A review
Couraud, S., Zalcman, G., Milleron, B. J., Morin, F., & Souquet, P.-J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.007 · Cited by 962
Metadata
- Authors
- Le Calvez, F., Mukeria, A., Hunt, J. D., Kelm, O., Hung, R. J., Tanière, P., Brennan, P., Boffetta, P., Zaridze, D. G., & Hainaut, P.
- Affiliations
- 1IARC, Lyon, France;
- Russian Cancer Research Center NN Blokhin (RU)
- Centre international de recherche sur le cancer (FR)
- 4Department of Cellular Pathology, The Medical School, University of Birmingham, Egbaston, Birmingham, United Kingdom
- ORCID
- Venue
- Cancer Research
- Published
- 2005-06-15
- Volume
- 65
- Issue
- 12
- Pages
- 5076-5083
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2149459560
- Cited by
- 273
- References
- 54
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 8 · 2023: 12 · 2022: 11 · 2021: 12 · 2020: 9 · 2019: 15 · 2018: 4 · 2017: 10 · 2016: 11 · 2015: 9 · 2014: 11 · 2013: 14 · 2012: 27
- FWCI
- 13.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- European Commission (IC15-CT96-0313)
- National Institutes of Health (5k01es000358-03)
- National Institute of Environmental Health Sciences (K01‐ES00358)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- TP53 mutation, KRAS mutation, lung cancer, smoking, mutation patterns, G:C to T:A transversions, cyclooxygenase-2, nitrotyrosine, nitric oxide, inflammation, never smokers, former smokers, squamous cell carcinoma, adenocarcinoma, lung carcinogenesis
- MeSH terms
- Aged, Female, Humans, Immunohistochemistry, Lung Neoplasms, Male, Membrane Proteins, Middle Aged, Mutation, Prostaglandin-Endoperoxide Synthases, Genes, ras, Smoking, Tyrosine, Genes, p53, Tumor Suppressor Protein p53, Cyclooxygenase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
